Korro Bio vs Entrada Therapeutics
KRRO and TRDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KRRO and TRDA compare
Korro Bio and Entrada Therapeutics are about the same size, with market caps of $212M and $212M.
Korro Bio grew revenue faster over the last twelve months (−82.5% versus −93.5% for Entrada Therapeutics).
Entrada Therapeutics keeps more of each dollar of sales as profit, with a net margin of −4058% compared with −8214% at Korro Bio.
Entrada Therapeutics scores higher on the StockData Score (6 against 5 for Korro Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KRRO | TRDA |
|---|---|---|
| Size and price | ||
| Market cap | $212M | $212M |
| Share price | $14.41 | $5.44 |
| Change, 1 year | −55.8% | −25.1% |
| Change, 5 years | −95.2% | −83.4% |
| Beta (5Y) | 2.11 | 0.97 |
| Employees | 58 | 152 |
| StockData Score | ||
| Total score | 5 | 6 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 164× | 53.3× (better) |
| P/B | – | 1.1× |
| FCF yield | −30.1% (better) | −64.4% |
| Growth | ||
| Revenue growth (TTM) | −82.5% (better) | −93.5% |
| Revenue growth, 5Y average | −29.6% | – |
| Profitability | ||
| Operating margin | −8467% | −4304% (better) |
| Net margin | −8214% | −4058% (better) |
| FCF margin | −4944% | −3428% (better) |
| Return on equity | – | −59.9% |
| Return on invested capital | – | −1406% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 7.30 | 7.85 (better) |
| Altman Z-score | −3.69 | −1.53 (better) |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 102% | 75.6% |
| Held by insiders | 27.5% | 14.8% |
| Insider net buying, 12 months | $16.0M (better) | −$11.5M |
| Short interest, % of float | 16.4% | 8.5% |
Go deeper
- KRRO stock overview
- KRRO income statement
- KRRO valuation and score
- TRDA stock overview
- TRDA income statement
- TRDA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.